Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM) on PET imaging of atherosclerosis
Cardiovascular diseases are the leading cause of death not only in Europe but also in the rest of the World. Preventive measures, however, often fail and cardiovascular disease may manifest as an acute coronary syndrome, stroke or even sudden death after years of silent progression. Thus, there is a...
Saved in:
| Published in | European journal of nuclear medicine and molecular imaging Vol. 43; no. 4; pp. 780 - 792 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.04.2016
Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Cardiovascular diseases are the leading cause of death not only in Europe but also in the rest of the World. Preventive measures, however, often fail and cardiovascular disease may manifest as an acute coronary syndrome, stroke or even sudden death after years of silent progression. Thus, there is a considerable need for innovative diagnostic and therapeutic approaches to improve the quality of care and limit the burden of cardiovascular diseases. During the past 10 years, several retrospective and prospective clinical studies have been published using
18
F-fluorodeoxyglucose (FDG) positron emission tomography (PET) to quantify inflammation in atherosclerotic plaques. However, the current variety of imaging protocols used for vascular (arterial) imaging with FDG PET considerably limits the ability to compare results between studies and to build large multicentre imaging registries. Based on the existing literature and the experience of the Members of the European Association of Nuclear Medicine (EANM) Cardiovascular Committee, the objective of this position paper was to propose optimized and standardized protocols for imaging and interpretation of PET scans in atherosclerosis. These recommendations do not, however, replace the individual responsibility of healthcare professionals to make appropriate decisions in the circumstances of the individual study protocols used and the individual patient, in consultation with the patient and, where appropriate and necessary, the patient’s guardian or carer. These recommendations suffer from the absence of conclusive evidence on many of the recommendations. Therefore, they are not intended and should not be used as "strict guidelines" but should, as already mentioned, provide a basis for standardized clinical atherosclerosis PET imaging protocols, which are subject to further and continuing evaluation and improvement. However, this EANM position paper might indeed be a first step towards "official" guidelines on atherosclerosis imaging with PET. |
|---|---|
| AbstractList | Cardiovascular diseases are the leading cause of death not only in Europe but also in the rest of the World. Preventive measures, however, often fail and cardiovascular disease may manifest as an acute coronary syndrome, stroke or even sudden death after years of silent progression. Thus, there is a considerable need for innovative diagnostic and therapeutic approaches to improve the quality of care and limit the burden of cardiovascular diseases. During the past 10 years, several retrospective and prospective clinical studies have been published using (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) to quantify inflammation in atherosclerotic plaques. However, the current variety of imaging protocols used for vascular (arterial) imaging with FDG PET considerably limits the ability to compare results between studies and to build large multicentre imaging registries. Based on the existing literature and the experience of the Members of the European Association of Nuclear Medicine (EANM) Cardiovascular Committee, the objective of this position paper was to propose optimized and standardized protocols for imaging and interpretation of PET scans in atherosclerosis. These recommendations do not, however, replace the individual responsibility of healthcare professionals to make appropriate decisions in the circumstances of the individual study protocols used and the individual patient, in consultation with the patient and, where appropriate and necessary, the patient's guardian or carer. These recommendations suffer from the absence of conclusive evidence on many of the recommendations. Therefore, they are not intended and should not be used as "strict guidelines" but should, as already mentioned, provide a basis for standardized clinical atherosclerosis PET imaging protocols, which are subject to further and continuing evaluation and improvement. However, this EANM position paper might indeed be a first step towards "official" guidelines on atherosclerosis imaging with PET.Cardiovascular diseases are the leading cause of death not only in Europe but also in the rest of the World. Preventive measures, however, often fail and cardiovascular disease may manifest as an acute coronary syndrome, stroke or even sudden death after years of silent progression. Thus, there is a considerable need for innovative diagnostic and therapeutic approaches to improve the quality of care and limit the burden of cardiovascular diseases. During the past 10 years, several retrospective and prospective clinical studies have been published using (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) to quantify inflammation in atherosclerotic plaques. However, the current variety of imaging protocols used for vascular (arterial) imaging with FDG PET considerably limits the ability to compare results between studies and to build large multicentre imaging registries. Based on the existing literature and the experience of the Members of the European Association of Nuclear Medicine (EANM) Cardiovascular Committee, the objective of this position paper was to propose optimized and standardized protocols for imaging and interpretation of PET scans in atherosclerosis. These recommendations do not, however, replace the individual responsibility of healthcare professionals to make appropriate decisions in the circumstances of the individual study protocols used and the individual patient, in consultation with the patient and, where appropriate and necessary, the patient's guardian or carer. These recommendations suffer from the absence of conclusive evidence on many of the recommendations. Therefore, they are not intended and should not be used as "strict guidelines" but should, as already mentioned, provide a basis for standardized clinical atherosclerosis PET imaging protocols, which are subject to further and continuing evaluation and improvement. However, this EANM position paper might indeed be a first step towards "official" guidelines on atherosclerosis imaging with PET. Cardiovascular diseases are the leading cause of death not only in Europe but also in the rest of the World. Preventive measures, however, often fail and cardiovascular disease may manifest as an acute coronary syndrome, stroke or even sudden death after years of silent progression. Thus, there is a considerable need for innovative diagnostic and therapeutic approaches to improve the quality of care and limit the burden of cardiovascular diseases. During the past 10 years, several retrospective and prospective clinical studies have been published using 18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET) to quantify inflammation in atherosclerotic plaques. However, the current variety of imaging protocols used for vascular (arterial) imaging with FDG PET considerably limits the ability to compare results between studies and to build large multicentre imaging registries. Based on the existing literature and the experience of the Members of the European Association of Nuclear Medicine (EANM) Cardiovascular Committee, the objective of this position paper was to propose optimized and standardized protocols for imaging and interpretation of PET scans in atherosclerosis. These recommendations do not, however, replace the individual responsibility of healthcare professionals to make appropriate decisions in the circumstances of the individual study protocols used and the individual patient, in consultation with the patient and, where appropriate and necessary, the patient’s guardian or carer. These recommendations suffer from the absence of conclusive evidence on many of the recommendations. Therefore, they are not intended and should not be used as "strict guidelines" but should, as already mentioned, provide a basis for standardized clinical atherosclerosis PET imaging protocols, which are subject to further and continuing evaluation and improvement. However, this EANM position paper might indeed be a first step towards "official" guidelines on atherosclerosis imaging with PET. Cardiovascular diseases are the leading cause of death not only in Europe but also in the rest of the World. Preventive measures, however, often fail and cardiovascular disease may manifest as an acute coronary syndrome, stroke or even sudden death after years of silent progression. Thus, there is a considerable need for innovative diagnostic and therapeutic approaches to improve the quality of care and limit the burden of cardiovascular diseases. During the past 10 years, several retrospective and prospective clinical studies have been published using (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) to quantify inflammation in atherosclerotic plaques. However, the current variety of imaging protocols used for vascular (arterial) imaging with FDG PET considerably limits the ability to compare results between studies and to build large multicentre imaging registries. Based on the existing literature and the experience of the Members of the European Association of Nuclear Medicine (EANM) Cardiovascular Committee, the objective of this position paper was to propose optimized and standardized protocols for imaging and interpretation of PET scans in atherosclerosis. These recommendations do not, however, replace the individual responsibility of healthcare professionals to make appropriate decisions in the circumstances of the individual study protocols used and the individual patient, in consultation with the patient and, where appropriate and necessary, the patient's guardian or carer. These recommendations suffer from the absence of conclusive evidence on many of the recommendations. Therefore, they are not intended and should not be used as "strict guidelines" but should, as already mentioned, provide a basis for standardized clinical atherosclerosis PET imaging protocols, which are subject to further and continuing evaluation and improvement. However, this EANM position paper might indeed be a first step towards "official" guidelines on atherosclerosis imaging with PET. Cardiovascular diseases are the leading cause of death not only in Europe but also in the rest of the World. Preventive measures, however, often fail and cardiovascular disease may manifest as an acute coronary syndrome, stroke or even sudden death after years of silent progression. Thus, there is a considerable need for innovative diagnostic and therapeutic approaches to improve the quality of care and limit the burden of cardiovascular diseases. During the past 10 years, several retrospective and prospective clinical studies have been published using super(18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) to quantify inflammation in atherosclerotic plaques. However, the current variety of imaging protocols used for vascular (arterial) imaging with FDG PET considerably limits the ability to compare results between studies and to build large multicentre imaging registries. Based on the existing literature and the experience of the Members of the European Association of Nuclear Medicine (EANM) Cardiovascular Committee, the objective of this position paper was to propose optimized and standardized protocols for imaging and interpretation of PET scans in atherosclerosis. These recommendations do not, however, replace the individual responsibility of healthcare professionals to make appropriate decisions in the circumstances of the individual study protocols used and the individual patient, in consultation with the patient and, where appropriate and necessary, the patient's guardian or carer. These recommendations suffer from the absence of conclusive evidence on many of the recommendations. Therefore, they are not intended and should not be used as "strict guidelines" but should, as already mentioned, provide a basis for standardized clinical atherosclerosis PET imaging protocols, which are subject to further and continuing evaluation and improvement. However, this EANM position paper might indeed be a first step towards "official" guidelines on atherosclerosis imaging with PET. Cardiovascular diseases are the leading cause of death not only in Europe but also in the rest of the World. Preventive measures, however, often fail and cardiovascular disease may manifest as an acute coronary syndrome, stroke or even sudden death after years of silent progression. Thus, there is a considerable need for innovative diagnostic and therapeutic approaches to improve the quality of care and limit the burden of cardiovascular diseases. During the past 10 years, several retrospective and prospective clinical studies have been published using ^sup 18^F-fluorodeoxyglucose (FDG) positron emission tomography (PET) to quantify inflammation in atherosclerotic plaques. However, the current variety of imaging protocols used for vascular (arterial) imaging with FDG PET considerably limits the ability to compare results between studies and to build large multicentre imaging registries. Based on the existing literature and the experience of the Members of the European Association of Nuclear Medicine (EANM) Cardiovascular Committee, the objective of this position paper was to propose optimized and standardized protocols for imaging and interpretation of PET scans in atherosclerosis. These recommendations do not, however, replace the individual responsibility of healthcare professionals to make appropriate decisions in the circumstances of the individual study protocols used and the individual patient, in consultation with the patient and, where appropriate and necessary, the patient's guardian or carer. These recommendations suffer from the absence of conclusive evidence on many of the recommendations. Therefore, they are not intended and should not be used as "strict guidelines" but should, as already mentioned, provide a basis for standardized clinical atherosclerosis PET imaging protocols, which are subject to further and continuing evaluation and improvement. However, this EANM position paper might indeed be a first step towards "official" guidelines on atherosclerosis imaging with PET. |
| Author | Bucerius, Jan Slart, Riemer H. J. A. Gimelli, Alessia Lindner, Oliver Übleis, Christopher Agostini, Denis Sciagra, Roberto Hyafil, Fabien Verberne, Hein J. Hacker, Marcus |
| Author_xml | – sequence: 1 givenname: Jan surname: Bucerius fullname: Bucerius, Jan email: jan.bucerius@mumc.nl organization: Department of Nuclear Medicine, Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, Department of Nuclear Medicine, University Hospital RWTH Aachen, RWTH Aachen, Department of Nuclear Medicine and Cardiovascular Research Institute (CARIM), Maastricht University Medical Center (MUMC+) – sequence: 2 givenname: Fabien surname: Hyafil fullname: Hyafil, Fabien organization: Department of Nuclear Medicine, Bichat University Hospital, Inserm 1148, DHU FIRE, Assistance Publique - Hôpitaux de Paris, Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München – sequence: 3 givenname: Hein J. surname: Verberne fullname: Verberne, Hein J. organization: Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam – sequence: 4 givenname: Riemer H. J. A. surname: Slart fullname: Slart, Riemer H. J. A. organization: Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Department of Biomedical Photonic Imaging, Faculty of Science and Technology, University of Twente – sequence: 5 givenname: Oliver surname: Lindner fullname: Lindner, Oliver organization: Nuclear Medicine and Molecular Imaging, Institute of Radiology, Heart and Diabetes Center NRW – sequence: 6 givenname: Roberto surname: Sciagra fullname: Sciagra, Roberto organization: Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence – sequence: 7 givenname: Denis surname: Agostini fullname: Agostini, Denis organization: Department of Nuclear Medicine, CHU Côte de Nacre, Normandie Université – sequence: 8 givenname: Christopher surname: Übleis fullname: Übleis, Christopher organization: Department of Clinical Radiology, Ludwig-Maximilians Universität München – sequence: 9 givenname: Alessia surname: Gimelli fullname: Gimelli, Alessia organization: Fondazione Toscana Gabriele Monasterio – sequence: 10 givenname: Marcus surname: Hacker fullname: Hacker, Marcus organization: Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided therapy, Medical University Vienna |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26678270$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkstu1DAUhi1URC_wAGxQJDZlETiOE182SKPRcJHa0kVZWx7nZOoqsQc7qcQT8No4nXZUKoHY2Jb-7_99fHyOyYEPHgl5TeE9BRAfEkDVqBJoU7L5wJ6RI8qpKgVIdbA_CzgkxyndAFBZSfWCHFacC1kJOCK_LkNyowu-2JotxiJ0xXiNxdLE1oVbk-zUm1gswzC4cUR80FdTDFs0vlikFKwzdwlZu5hsj9lwjq2zzmNxulpcnL8rsnq5uircYDbOb2bS5JgYUsbz6tJL8rwzfcJX9_sJ-f5pdbX8Up59-_x1uTgrLVf1WFK1rqRsTGMkM60C1TK2llArqLFTxkphrQSEjla2RmyYpKzrrMpawxpWsxPycZe7ndYDthb9GE2vtzGXFn_qYJz-U_HuWm_Cra4Fr3klcsDpfUAMPyZMox5cstj3xmOYkqZCcF5LDvI_UC4p5xJURt8-QW_CFH3uxBwIUrKqhky9eVz8vuqH78wA3QE2NzVF7PYIBT2PjN6NjM4jo-eR0Sx7xBOPdePdh-b3u_6fzmrnTPkWv8H4qOi_mn4DZXDVXQ |
| CitedBy_id | crossref_primary_10_1002_art_40379 crossref_primary_10_1016_j_remnie_2019_06_001 crossref_primary_10_1007_s12350_019_01943_1 crossref_primary_10_1007_s12350_022_03041_1 crossref_primary_10_1007_s13139_016_0418_9 crossref_primary_10_3389_fmed_2024_1469964 crossref_primary_10_3390_ijms22115876 crossref_primary_10_1053_j_semnuclmed_2023_10_005 crossref_primary_10_1093_eurheartj_ehac102 crossref_primary_10_1093_qjmed_hcz036 crossref_primary_10_1136_bmjopen_2020_038607 crossref_primary_10_3390_cells12162073 crossref_primary_10_1161_CIRCIMAGING_122_014544 crossref_primary_10_1002_adfm_201603084 crossref_primary_10_1186_s13550_017_0285_0 crossref_primary_10_1038_s41598_021_96923_2 crossref_primary_10_1093_ehjci_jew219 crossref_primary_10_1136_bmjopen_2022_062602 crossref_primary_10_1161_ATVBAHA_116_307293 crossref_primary_10_1016_j_remn_2019_03_002 crossref_primary_10_1038_s41598_021_81144_4 crossref_primary_10_1186_s13550_023_00951_0 crossref_primary_10_1089_thy_2024_0476 crossref_primary_10_1093_rheumatology_keae450 crossref_primary_10_1097_MD_0000000000023259 crossref_primary_10_1039_D1MH00880C crossref_primary_10_1007_s11886_020_01375_1 crossref_primary_10_3389_fimmu_2022_821423 crossref_primary_10_1007_s00259_024_06946_w crossref_primary_10_3390_jcm9051393 crossref_primary_10_1007_s12149_021_01651_2 crossref_primary_10_1007_s12350_021_02543_8 crossref_primary_10_1007_s10554_021_02348_3 crossref_primary_10_1053_j_semnuclmed_2020_02_017 crossref_primary_10_1093_ehjci_jeaa299 crossref_primary_10_3390_app9040657 crossref_primary_10_7554_eLife_60939 crossref_primary_10_3390_ijms241311123 crossref_primary_10_3390_jcm10235515 crossref_primary_10_1007_s10741_017_9625_4 crossref_primary_10_1016_j_echo_2020_04_021 crossref_primary_10_4078_jrd_2020_27_3_136 crossref_primary_10_1007_s12350_019_01842_5 crossref_primary_10_1177_1358863X241287692 crossref_primary_10_3390_biom10121629 crossref_primary_10_1016_j_ejvs_2018_03_028 crossref_primary_10_1007_s12350_017_1060_3 crossref_primary_10_1097_nm9_0000000000000016 crossref_primary_10_1007_s13300_025_01710_1 crossref_primary_10_1097_BOR_0000000000000852 crossref_primary_10_1007_s40336_021_00476_3 crossref_primary_10_1161_CIRCIMAGING_117_007394 crossref_primary_10_1016_j_jacc_2018_12_075 crossref_primary_10_1161_CIRCIMAGING_124_016851 crossref_primary_10_1161_CIRCIMAGING_118_007849 crossref_primary_10_1016_j_atherosclerosis_2019_04_209 crossref_primary_10_1021_acsami_8b08975 crossref_primary_10_1055_a_2390_2829 crossref_primary_10_1016_j_jid_2017_05_034 crossref_primary_10_1161_CIRCRESAHA_116_307971 crossref_primary_10_1007_s00259_023_06245_w crossref_primary_10_1007_s11307_016_1036_8 crossref_primary_10_1007_s12350_020_02055_x crossref_primary_10_3389_fbioe_2021_640037 crossref_primary_10_1007_s00259_017_3747_8 crossref_primary_10_1177_0003319720965419 crossref_primary_10_1007_s00259_022_05991_7 crossref_primary_10_1007_s12350_017_1121_7 crossref_primary_10_1016_j_atherosclerosis_2017_05_017 crossref_primary_10_1007_s40336_020_00370_4 crossref_primary_10_1186_s13550_017_0287_y crossref_primary_10_23736_S1824_4785_20_03231_8 crossref_primary_10_1007_s11926_020_00955_y crossref_primary_10_1007_s12350_020_02522_5 crossref_primary_10_1136_rmdopen_2021_001804 crossref_primary_10_1371_journal_pone_0187995 crossref_primary_10_1007_s12149_022_01800_1 crossref_primary_10_1016_j_semarthrit_2017_08_009 crossref_primary_10_1038_s41598_021_00999_9 crossref_primary_10_1016_j_jacc_2022_10_034 crossref_primary_10_1007_s12350_017_1077_7 crossref_primary_10_3390_bioengineering10050521 crossref_primary_10_3390_life11040305 crossref_primary_10_1016_j_cpet_2019_11_009 crossref_primary_10_1186_s41824_019_0053_7 crossref_primary_10_1016_j_ijcard_2020_09_035 crossref_primary_10_1097_MNM_0000000000001468 crossref_primary_10_1007_s12149_022_01752_6 crossref_primary_10_1097_HJH_0000000000002727 crossref_primary_10_1007_s10554_018_01514_4 crossref_primary_10_23736_S1824_4785_20_03228_8 crossref_primary_10_5664_jcsm_9382 crossref_primary_10_1007_s12350_021_02887_1 crossref_primary_10_3389_fstro_2023_1241506 crossref_primary_10_1186_s12880_025_01617_0 crossref_primary_10_2967_jnumed_122_264868 crossref_primary_10_1016_j_semarthrit_2019_07_008 crossref_primary_10_1016_j_atherosclerosis_2017_11_016 crossref_primary_10_1186_s12872_022_02534_8 crossref_primary_10_1161_ATVBAHA_119_312586 crossref_primary_10_1007_s00259_017_3917_8 crossref_primary_10_1016_j_atherosclerosis_2022_06_1014 crossref_primary_10_1038_s41598_023_45110_6 crossref_primary_10_2459_JCM_0000000000001314 crossref_primary_10_3390_diagnostics14222486 crossref_primary_10_1016_j_jacc_2017_01_060 crossref_primary_10_1007_s00259_018_4176_z crossref_primary_10_1097_MNM_0000000000000867 crossref_primary_10_1007_s00259_023_06168_6 crossref_primary_10_1186_s13075_021_02585_w crossref_primary_10_3390_biology10111206 crossref_primary_10_1093_cvr_cvad109 crossref_primary_10_1111_cns_70312 crossref_primary_10_1016_j_jcmg_2016_04_007 crossref_primary_10_3390_ijms231810268 crossref_primary_10_1007_s00259_019_04292_w crossref_primary_10_1007_s12350_021_02812_6 crossref_primary_10_3390_diagnostics11111993 crossref_primary_10_22141_2224_1507_11_1_2021_226904 crossref_primary_10_3390_jpm11030236 crossref_primary_10_1016_j_ymeth_2020_10_004 crossref_primary_10_1007_s12350_022_02985_8 crossref_primary_10_1016_j_atherosclerosis_2024_118595 crossref_primary_10_1007_s12350_018_1247_2 crossref_primary_10_3390_diagnostics14101006 crossref_primary_10_1007_s12350_018_1289_5 crossref_primary_10_1007_s12350_022_02962_1 crossref_primary_10_1093_cvr_cvad058 crossref_primary_10_1259_bjr_20230704 crossref_primary_10_3390_life14010146 crossref_primary_10_1016_j_ymeth_2017_06_008 crossref_primary_10_1007_s00259_018_3973_8 crossref_primary_10_1111_all_14859 crossref_primary_10_1038_nrneurol_2017_129 crossref_primary_10_1111_bjd_15149 crossref_primary_10_3390_ijms24032245 crossref_primary_10_1007_s00259_020_05066_5 crossref_primary_10_3389_fneur_2021_731744 crossref_primary_10_1007_s12149_020_01458_7 crossref_primary_10_1212_WNL_0000000000012909 crossref_primary_10_1097_RHU_0000000000001801 crossref_primary_10_1007_s12350_020_02257_3 crossref_primary_10_1161_CIRCIMAGING_120_012174 crossref_primary_10_2967_jnumed_119_234484 crossref_primary_10_1042_CS20241529 crossref_primary_10_4081_br_2021_70 crossref_primary_10_1016_j_ccr_2020_213344 crossref_primary_10_2967_jnumed_116_179663 crossref_primary_10_4068_cmj_2021_57_2_139 crossref_primary_10_1007_s00259_017_3831_0 crossref_primary_10_1007_s12350_019_01833_6 crossref_primary_10_1016_j_jacl_2017_10_019 crossref_primary_10_1210_clinem_dgz306 crossref_primary_10_1038_s41598_019_51800_x crossref_primary_10_1016_j_jcmg_2019_03_031 crossref_primary_10_1097_RLU_0000000000004050 crossref_primary_10_1186_s13550_019_0567_9 crossref_primary_10_1007_s40336_019_00334_3 crossref_primary_10_1038_s41598_023_49585_1 crossref_primary_10_3390_life12071039 crossref_primary_10_1007_s12350_020_02248_4 crossref_primary_10_1161_HYPERTENSIONAHA_122_17964 crossref_primary_10_2967_jnumed_122_264550 crossref_primary_10_1177_2048004020980941 crossref_primary_10_37336_2707_0700_2019_3_5 crossref_primary_10_3389_fimmu_2021_695227 crossref_primary_10_1186_s12880_023_01134_y crossref_primary_10_3390_biomedicines12040861 crossref_primary_10_1038_s41598_021_93605_x crossref_primary_10_1007_s10554_022_02743_4 crossref_primary_10_1007_s12350_022_03116_z crossref_primary_10_3390_ijms232415528 crossref_primary_10_1016_j_atherosclerosis_2017_04_024 crossref_primary_10_1016_j_jacl_2023_08_004 crossref_primary_10_1136_rmdopen_2023_003547 crossref_primary_10_1007_s00259_024_06597_x crossref_primary_10_1161_ATVBAHA_117_309227 crossref_primary_10_1186_s13550_020_00661_x crossref_primary_10_1513_AnnalsATS_202309_821OC crossref_primary_10_1016_j_jacc_2017_07_750 crossref_primary_10_1007_s11604_024_01636_x crossref_primary_10_1016_j_jacadv_2022_100164 crossref_primary_10_1007_s12350_019_01905_7 crossref_primary_10_2967_jnumed_121_262863 crossref_primary_10_2196_28669 |
| Cites_doi | 10.1007/s00259-013-2569-6 10.3413/nukmed-0299 10.2967/jnumed.109.070672 10.1016/j.jacc.2007.03.003 10.1088/0031-9155/58/21/7527 10.2967/jnumed.115.154385 10.1016/j.jacc.2010.09.056 10.1097/00006231-200206000-00006 10.1056/NEJM199907223410406 10.1007/s00259-009-1152-7 10.1016/j.atherosclerosis.2015.02.027 10.1038/nature00804 10.1161/ATVBAHA.108.165563 10.1038/nm1700 10.1016/S0140-6736(11)61383-4 10.1097/00006231-200110000-00011 10.1007/s00259-011-1994-7 10.1016/j.jcmg.2013.08.006 10.1161/CIRCIMAGING.113.000382 10.1016/S0140-6736(13)61754-7 10.1056/NEJMp068182 10.1161/CIR.0000000000000152 10.7150/thno.5629 10.2967/jnumed.110.081208 10.1016/j.atherosclerosis.2015.03.039 10.1016/j.jacc.2006.03.069 10.2967/jnumed.114.142596 10.2967/jnumed.107.050294 10.1002/ana.23553 10.1038/ncomms8495 10.1016/j.jacc.2007.05.024 10.1161/01.ATV.0000178991.71605.18 10.1016/S0092-8674(01)00238-0 10.1007/s12350-015-0069-8 10.2967/jnumed.109.065151 10.1161/01.STR.0000190896.67743.b1 10.1016/j.jcmg.2014.03.018 10.2967/jnumed.108.061432 10.1007/s002590100517 10.1161/CIRCIMAGING.113.001093 10.1016/j.ahj.2011.05.006 10.1002/jso.20624 10.1016/j.jacc.2013.08.1627 10.1007/s12350-014-9884-6 10.1016/j.jacc.2013.07.050 10.1038/nrcardio.2014.80-c2 10.2967/jnumed.112.112524 10.1088/0031-9155/59/5/1203 10.2967/jnumed.106.035774 10.1161/CIRCIMAGING.110.959478 10.1016/j.jacc.2006.05.076 10.1016/j.clinthera.2010.12.001 10.1161/ATVBAHA.114.305067 10.1097/MNM.0b013e32833767e0 10.1007/s00259-007-0685-x 10.2967/jnumed.109.074294 10.2967/jnumed.112.105353 10.1161/STROKEAHA.108.521393 10.1016/j.jacc.2011.11.069 10.1161/01.CIR.0000020548.60110.76 10.2967/jnumed.109.066456 10.1016/j.jcmg.2010.01.001 10.1007/s00259-013-2653-y 10.2967/jnumed.110.076471 10.1016/j.atherosclerosis.2006.10.027 10.1097/MD.0000000000000725 10.1016/j.jcmg.2012.02.016 10.1097/00041433-200310000-00004 10.1016/j.nuclcard.2005.03.002 10.1007/s00259-014-2961-x 10.1016/j.jacc.2013.04.066 10.1088/0031-9155/57/21/R119 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2015 Springer-Verlag Berlin Heidelberg 2016 |
| Copyright_xml | – notice: The Author(s) 2015 – notice: Springer-Verlag Berlin Heidelberg 2016 |
| CorporateAuthor | on behalf of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM) Cardiovascular Committee of the European Association of Nuclear Medicine (EANM) |
| CorporateAuthor_xml | – name: on behalf of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM) – name: Cardiovascular Committee of the European Association of Nuclear Medicine (EANM) |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7TK 7X7 7XB 88E 8AO 8FE 8FG 8FH 8FI 8FJ 8FK ABUWG AFKRA ARAPS AZQEC BBNVY BENPR BGLVJ BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. KB0 LK8 M0S M1P M7P NAPCQ P5Z P62 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 7QO 8FD FR3 P64 5PM |
| DOI | 10.1007/s00259-015-3259-3 |
| DatabaseName | Springer Nature Link OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection ProQuest Central Essentials Biological Science Collection ProQuest Central Technology Collection Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences ProQuest Health & Medical Collection Medical Database Biological Science Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic Biotechnology Research Abstracts Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student Technology Collection ProQuest One Academic Middle East (New) ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Advanced Technologies & Aerospace Collection ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Advanced Technologies & Aerospace Database Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic Engineering Research Database Biotechnology Research Abstracts Technology Research Database Biotechnology and BioEngineering Abstracts |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Engineering Research Database ProQuest Central Student |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1619-7089 |
| EndPage | 792 |
| ExternalDocumentID | PMC4764627 3972564781 26678270 10_1007_s00259_015_3259_3 |
| Genre | Guideline Journal Article Feature |
| GroupedDBID | --- -5E -5G -BR -Y2 -~C .86 .GJ .VR 04C 06C 06D 0R~ 0VY 199 1N0 203 29G 29~ 2JN 2JY 2KM 2LR 2P1 2VQ 2~H 30V 36B 3V. 4.4 406 40D 53G 5GY 5QI 5RE 5VS 67Z 6NX 78A 7RV 7X7 88E 8AO 8FE 8FG 8FH 8FI 8FJ 8UJ 95- 95. 95~ 96X AAAVM AACDK AAHNG AAIAL AAJBT AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDBF ABECU ABFTV ABHQN ABIPD ABJNI ABJOX ABKCH ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHVE ACIWK ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACUDM ACUHS ACZOJ ADBBV ADHIR ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AEVLU AEXYK AFBBN AFEXP AFFNX AFJLC AFKRA AFLOW AFQWF AFRAH AFWTZ AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGVAE AGWIL AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AOCGG ARAPS ARMRJ AXYYD AZFZN B-. B0M BA0 BBNVY BDATZ BENPR BGLVJ BGNMA BHPHI BKEYQ BMSDO BPHCQ BSONS BVXVI C6C CAG CCPQU COF CSCUP DDRTE DL5 DNIVK DPUIP DU5 EAD EAP EAS EBB EBC EBD EBLON EBO EBS EBX EHN EIHBH EIOEI EJD EMB EMK EMOBN EN4 EPL EPT ESBYG ESX EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GNWQR GQ6 GQ7 GQ8 GRRUI GXS H13 HCIFZ HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KPH LAS LK8 LLZTM M1P M4Y M7P MA- N2Q N9A NAPCQ NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P62 P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS Q~Q R89 R9I RNI RNS ROL RPX RRX RSV RZK S1Z S26 S27 S28 S37 S3B SAP SCLPG SDH SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TH9 TSG TSK TT1 TUS U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WK8 WOW YLTOR Z45 Z7R Z7U Z7W Z7X Z7Y Z7Z Z81 Z82 Z83 Z87 Z88 Z8M Z8O Z8Q Z8R Z8S Z8T Z8U Z8V Z8W Z8Z Z91 ZMTXR ~8M AAPKM AAYXX ABBRH ABDBE ABFSG ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT ABRTQ CGR CUY CVF ECM EIF NPM PJZUB PPXIY PQGLB 7TK 7XB 8FK AZQEC DWQXO GNUQQ K9. PKEHL PQEST PQUKI PRINS 7X8 7QO 8FD FR3 P64 5PM |
| ID | FETCH-LOGICAL-c694t-19b2885a5a83ad909d33b804904ef9ac87cc80e0f12c4ee53813ffc9f9a535343 |
| IEDL.DBID | 7X7 |
| ISSN | 1619-7070 1619-7089 |
| IngestDate | Thu Aug 21 14:13:07 EDT 2025 Fri Jul 11 07:59:24 EDT 2025 Mon Jul 21 11:03:19 EDT 2025 Sat Aug 23 14:46:59 EDT 2025 Mon Jul 21 06:04:26 EDT 2025 Tue Jul 01 02:19:47 EDT 2025 Thu Apr 24 23:05:30 EDT 2025 Fri Feb 21 02:43:40 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | Position paper Positron emission tomography Atherosclerosis |
| Language | English |
| License | Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c694t-19b2885a5a83ad909d33b804904ef9ac87cc80e0f12c4ee53813ffc9f9a535343 |
| Notes | SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-2 ObjectType-Instructional Material/Guideline-1 ObjectType-Feature-3 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
| OpenAccessLink | https://doi.org/10.1007/s00259-015-3259-3 |
| PMID | 26678270 |
| PQID | 1770883240 |
| PQPubID | 42802 |
| PageCount | 13 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4764627 proquest_miscellaneous_1776648608 proquest_miscellaneous_1768166809 proquest_journals_1770883240 pubmed_primary_26678270 crossref_primary_10_1007_s00259_015_3259_3 crossref_citationtrail_10_1007_s00259_015_3259_3 springer_journals_10_1007_s00259_015_3259_3 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2016-04-01 |
| PublicationDateYYYYMMDD | 2016-04-01 |
| PublicationDate_xml | – month: 04 year: 2016 text: 2016-04-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Berlin/Heidelberg |
| PublicationPlace_xml | – name: Berlin/Heidelberg – name: Germany – name: Heidelberg |
| PublicationTitle | European journal of nuclear medicine and molecular imaging |
| PublicationTitleAbbrev | Eur J Nucl Med Mol Imaging |
| PublicationTitleAlternate | Eur J Nucl Med Mol Imaging |
| PublicationYear | 2016 |
| Publisher | Springer Berlin Heidelberg Springer Nature B.V |
| Publisher_xml | – name: Springer Berlin Heidelberg – name: Springer Nature B.V |
| References | FayadZAManiVWoodwardMKallendDBansilalSPozzaJRationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomographyAm Heart J2011162214221404782010.1016/j.ahj.2011.05.006218352801:CAS:528:DC%2BC3MXhtVajtrvF BaiBBadingJContiPSTumor quantification in clinical positron emission tomographyTheranostics20133787801384041210.7150/thno.562924312151 BuceriusJManiVMoncrieffCRuddJHMachacJFusterVImpact of non insulin-dependent type 2 diabetes on carotid wall (18)F-fluorodeoxyglucose positron emission tomography uptakeJ Am Coll Cardiol20125920802088339220210.1016/j.jacc.2011.11.06922651864 ErlandssonKBuvatIPretoriusPHThomasBAHuttonBFA review of partial volume correction techniques for emission tomography and their applications in neurology, cardiology and oncologyPhys Med Biol201257R119R15910.1088/0031-9155/57/21/R11923073343 ZhaoSKugeYTsukamotoEMochizukiTKatoTHikosakaKFluorodeoxyglucose uptake and glucose transporter expression in experimental inflammatory lesions and malignant tumours: effects of insulin and glucose loadingNucl Med Commun20022354555010.1097/00006231-200206000-00006120292091:CAS:528:DC%2BD38XntFSmur4%3D RomingerASaamTWolpersSCyranCCSchmidtMFoersterS18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic diseaseJ Nucl Med2009501611162010.2967/jnumed.109.06515119759117 RuddJHMyersKSBansilalSMachacJPintoCATongCAtherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendationsJ Nucl Med20084987187810.2967/jnumed.107.05029418483100 SkålénKGustafssonMRydbergEKHulténLMWiklundOInnerarityTLSubendothelial retention of atherogenic lipoproteins in early atherosclerosisNature200241775075410.1038/nature00804120661871:CAS:528:DC%2BD38XksVGjuro%3D TawakolASinghPRuddJHSofferJCaiGVucicEEffect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with (18)F-fluorodeoxyglucose-positron emission tomography imagingJ Am Coll Cardiol201463868810.1016/j.jacc.2013.07.050239736981:CAS:528:DC%2BC2cXltVSmsw%3D%3D RuddJHWarburtonEAFryerTDJonesHAClarkJCAntounNImaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomographyCirculation20021052708271110.1161/01.CIR.0000020548.60110.76120579821:STN:280:DC%2BD38zhsFCisg%3D%3D RuddJHMyersKSBansilalSMachacJRafiqueAFarkouhM(18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trialsJ Am Coll Cardiol20075089289610.1016/j.jacc.2007.05.02417719477 PedersenSFGraebeMFisker HagAMHøjgaardLSillesenHKjaerAGene expression and 18FDG uptake in atherosclerotic carotid plaquesNucl Med Commun201031423429201455771:CAS:528:DC%2BC3cXmtVWjsLw%3D JudenhoferMSWehrlHFNewportDFCatanaCSiegelSBBeckerMSimultaneous PET-MRI: a new approach for functional and morphological imagingNat Med20081445946510.1038/nm1700183764101:CAS:528:DC%2BD1cXktl2is7k%3D KimEJKimSKangDOSeoHSMetabolic activity of the spleen and bone marrow in patients with acute myocardial infarction evaluated by 18F-fluorodeoxyglucose positron emission tomographic imagingCirc Cardiovasc Imaging2014745446010.1161/CIRCIMAGING.113.00109324488982 DerlinTRichterUBannasPBegemannPBuchertRMesterJFeasibility of 18F-sodium fluoride PET/CT for imaging of atherosclerotic plaqueJ Nucl Med20105186286510.2967/jnumed.110.07647120484438 EmamiHVucicESubramanianSAbdelbakyAFayadZADuSThe effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: a multicenter FDG-PET trialAtherosclerosis201524049049610.1016/j.atherosclerosis.2015.03.039259136641:CAS:528:DC%2BC2MXls1Gmsr8%3D FörsterSRomingerASaamTWolpersSNikolaouKCummingP18F-fluoroethylcholine uptake in arterial vessel walls and cardiovascular risk factors. Correlation in a PET-CT studyNuklearmedizin20104914815310.3413/nukmed-029920532464 ZhuangHMCortés-BlancoAPourdehnadMAdamLEYamamotoAJMartínez-LázaroRDo high glucose levels have differential effect on FDG uptake in inflammatory and malignant disorders?Nucl Med Commun2001221123112810.1097/00006231-200110000-00011115671861:STN:280:DC%2BD3MritVWhug%3D%3D KatoKSchoberOIkedaMSchäfersMIshigakiTKiesPEvaluation and comparison of 11C-choline uptake and calcification in aortic and common carotid arterial walls with combined PET/CTEur J Nucl Med Mol Imaging2009361622162810.1007/s00259-009-1152-7194307851:CAS:528:DC%2BD1MXht1WhtLzK JoshiNVVeseyATWilliamsMCShahASCalvertPACraigheadFH18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trialLancet201438370571310.1016/S0140-6736(13)61754-724224999 VirmaniRKolodgieFDBurkeAPFinnAVGoldHKTulenkoTNAtherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhageArterioscler Thromb Vasc Biol2005252054206110.1161/01.ATV.0000178991.71605.18160375671:CAS:528:DC%2BD2MXhtVCltrvL HuetPBurgSLe GuludecDHyafilFBuvatIVariability and uncertainty of 18F-FDG PET imaging protocols for assessing inflammation in atherosclerosis: suggestions for improvementJ Nucl Med20155655255910.2967/jnumed.114.142596257224521:CAS:528:DC%2BC2MXmvVWmtLc%3D GaztanagaJFarkouhMRuddJHBrotzTMRosenbaumDManiVA phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndromeAtherosclerosis2015240536010.1016/j.atherosclerosis.2015.02.027257524381:CAS:528:DC%2BC2MXjsVGntLg%3D RabkinZIsraelOKeidarZDo hyperglycemia and diabetes affect the incidence of false-negative 18F-FDG PET/CT studies in patients evaluated for infection or inflammation and cancer? A comparative analysisJ Nucl Med2010511015102010.2967/jnumed.109.07429420554733 TawakolAFayadZAMoggRAlonAKlimasMTDanskyHIntensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility studyJ Am Coll Cardiol20136290991710.1016/j.jacc.2013.04.066237270831:CAS:528:DC%2BC3sXhtlClu7zP FayadZAManiVWoodwardMKallendDAbtMBurgessTSafety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trialLancet201137815471559415187510.1016/S0140-6736(11)61383-4219080361:CAS:528:DC%2BC3MXhtlyktr7P BuceriusJSchmaljohannJBöhmIGuhlkeSPalmedoHSchildHHFeasibility of 18-F-Fluoromethylcholine PET/CT for imaging of vessel wall alterations in humans – first resultsEur J Nucl Med Mol Imaging20083581582010.1007/s00259-007-0685-x18183393 ShaddingerBCXuYRogerJHMacpheeCHHandelMBaidooCAPlatelet aggregation unchanged by lipoprotein-associated phospholipase A2 inhibition: results from an in vitro study and two randomized phase I trialsPLoS One201427e8309 IshiiHNishioMTakahashiHAoyamaTTanakaMToriyamaTComparison of atorvastatin 5 and 20 mg/d for reducing F-18 fluorodeoxyglucose uptake in atherosclerotic plaques on positron emission tomography/computed tomography: a randomized, investigator-blinded, open-label, 6-month study in Japanese adults scheduled for percutaneous coronary interventionClin Ther2010322337234710.1016/j.clinthera.2010.12.001213531041:CAS:528:DC%2BC3MXisFKjsrw%3D RomingerASaamTVoglEÜbleisCla FougèreCFörsterSIn vivo imaging of macrophage activity in the coronary arteries using 68Ga-DOTATATE PET/CT: correlation with coronary calcium burden and risk factorsJ Nucl Med20105119319710.2967/jnumed.109.07067220080898 BoellaardRDelgado-BoltonROyenWJGiammarileFTatschKEschnerWFDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0Eur J Nucl Med Mol Imaging201542328354431552910.1007/s00259-014-2961-x254522191:CAS:528:DC%2BC2cXitVWhu7rL PetibonYEl FakhriGNezafatRJohnsonNBradyTOuyangJTowards coronary plaque imaging using simultaneous PET-MR: a simulation studyPhys Med Biol20145912031222406160710.1088/0031-9155/59/5/1203245566081:STN:280:DC%2BC2cvmvFChtA%3D%3D ZhaoQMFengTTZhaoXXuZMLiuYLiDPImaging of atherosclerotic aorta of rabbit model by detection of plaque inflammation with fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomographyChin Med J (Engl)20111249119171:CAS:528:DC%2BC3MXltleqtLo%3D DaviesJRRuddJHFryerTDGravesMJClarkJCKirkpatrickPJIdentification of culprit lesions after transient ischemic attack by combined 18F fluorodeoxyglucose positron-emission tomography and high-resolution magnetic resonance imagingStroke2005362642264710.1161/01.STR.0000190896.67743.b116282536 TarkinJMRuddJHTechniques for noninvasive molecular imaging of atherosclerotic plaqueNat Rev Cardiol2014127910.1038/nrcardio.2014.80-c225488268 FiferKMQadirSSubramanianSVijayakumarJFigueroaALTruongQAPositron emission tomography measurement of periodontal 18F-fluorodeoxyglucose uptake is associated with histologically determined carotid plaque inflammationJ Am Coll Cardiol20115797197610.1016/j.jacc.2010.09.05621329844 ZhaoSKugeYTsukamotoEMochizukiTKatoTHikosakaKEffects of insulin and glucose loading on FDG uptake in experimental malignant tumours and inflammatory lesionsEur J Nucl Med20012873073510.1007/s002590100517114400331:CAS:528:DC%2BD3MXktlaksr4%3D Rudd JH, Fayad ZA, Machac J, Weissberg PL, Davies JR, Warburton EA, et al. Response to 'Laurberg JM, Olsen AK, Hansen SB, Bottcher M, Morrison M, Ricketts SA, Falk E. Imaging of vulnerable atherosclerotic plaques with FDG-microPET: no FDG accumulation' [Atherosclerosis 2006]. Atherosclerosis. 2007;192:453–4. Author reply 451–2. IrkleAVeseyATLewisDYSkepperJNBirdJLDweckMRIdentifying active vascular microcalcification by (18)F-sodium fluoride positron emission tomographyNat Commun201567495450699710.1038/ncomms84 S Zhao (3259_CR28) 2002; 23 K Skålén (3259_CR4) 2002; 417 M Elkhawad (3259_CR47) 2012; 5 A Tawakol (3259_CR64) 2014; 63 S Gholami (3259_CR38) 2015; 22 ZA Fayad (3259_CR61) 2011; 162 S Folke Pedersen (3259_CR72) 2015; 35 Z Rabkin (3259_CR22) 2010; 51 S Burg (3259_CR33) 2013; 58 D Izquierdo-Garcia (3259_CR36) 2009; 40 J Bucerius (3259_CR45) 2015; 94 PR Shepherd (3259_CR25) 1999; 341 Y Petibon (3259_CR35) 2014; 59 HM Zhuang (3259_CR23) 2001; 22 K Erlandsson (3259_CR31) 2012; 57 BA Blomberg (3259_CR20) 2014; 21 A Tawakol (3259_CR50) 2013; 62 T Derlin (3259_CR73) 2010; 51 AL Figueroa (3259_CR10) 2012; 5 H Emami (3259_CR52) 2015; 240 A Tawakol (3259_CR21) 2005; 12 JH Rudd (3259_CR40) 2007; 50 ZA Fayad (3259_CR62) 2011; 378 H Ishii (3259_CR59) 2010; 32 R Boellaard (3259_CR29) 2015; 42 NV Joshi (3259_CR76) 2014; 383 MS Judenhofer (3259_CR66) 2008; 14 GF Anderson (3259_CR2) 2007; 356 M Marnane (3259_CR56) 2012; 71 3259_CR17 3259_CR1 3259_CR16 WW Lee (3259_CR24) 2006; 94 B Bai (3259_CR43) 2013; 3 J Bucerius (3259_CR13) 2014; 41 LJ Menezes (3259_CR15) 2009; 50 A Irkle (3259_CR74) 2015; 6 R Virmani (3259_CR7) 2005; 25 YI Miller (3259_CR6) 2003; 14 J Bucerius (3259_CR30) 2012; 59 D Mozaffarian (3259_CR3) 2015; 131 S Zhao (3259_CR27) 2001; 28 JR Davies (3259_CR11) 2005; 36 K Kato (3259_CR69) 2009; 36 JH Rudd (3259_CR42) 2008; 49 J Gaztanaga (3259_CR63) 2015; 240 KM Fifer (3259_CR12) 2011; 57 J Bucerius (3259_CR68) 2008; 35 JH Rudd (3259_CR14) 2002; 105 F Jamar (3259_CR26) 2013; 54 EJ Kim (3259_CR46) 2014; 7 M Soret (3259_CR32) 2007; 48 H Emami (3259_CR49) 2014; 7 S Subramanian (3259_CR48) 2013; 62 M Ogawa (3259_CR37) 2004; 45 A Rominger (3259_CR55) 2009; 50 JH Rudd (3259_CR18) 2009; 50 P Huet (3259_CR34) 2015; 56 J Bucerius (3259_CR44) 2014; 41 QM Zhao (3259_CR39) 2011; 124 A Tawakol (3259_CR9) 2006; 48 T Derlin (3259_CR75) 2011; 52 AL Figueroa (3259_CR41) 2013; 6 A Abdelbaky (3259_CR57) 2013; 6 JH Rudd (3259_CR8) 2009; 29 YW Wu (3259_CR60) 2011; 39 BC Shaddinger (3259_CR65) 2014; 27 C Rischpler (3259_CR67) 2013; 54 CK Glass (3259_CR5) 2001; 104 S Förster (3259_CR70) 2010; 49 A Rominger (3259_CR71) 2010; 51 N Tahara (3259_CR19) 2006; 48 W Chen (3259_CR51) 2015; 56 M Graebe (3259_CR53) 2010; 3 SF Pedersen (3259_CR54) 2010; 31 JM Tarkin (3259_CR58) 2014; 12 20532464 - Nuklearmedizin. 2010;49(4):148-53 19759117 - J Nucl Med. 2009 Oct;50(10):1611-20 25722451 - J Nucl Med. 2015 Apr;56(4):503-4 23833282 - Circ Cardiovasc Imaging. 2013 Sep;6(5):747-54 18483100 - J Nucl Med. 2008 Jun;49(6):871-8 22974804 - JACC Cardiovasc Imaging. 2012 Sep;5(9):911-22 24633502 - J Nucl Cardiol. 2014 Jun;21(3):588-97 20145577 - Nucl Med Commun. 2010 May;31(5):423-9 19304673 - Arterioscler Thromb Vasc Biol. 2009 Jul;29(7):1009-16 25520374 - Circulation. 2015 Jan 27;131(4):e29-322 26151378 - Nat Commun. 2015;6:7495 25913664 - Atherosclerosis. 2015 Jun;240(2):490-6 14501582 - Curr Opin Lipidol. 2003 Oct;14(5):437-45 16037567 - Arterioscler Thromb Vasc Biol. 2005 Oct;25(10):2054-61 24312151 - Theranostics. 2013;3(10):787-801 25452219 - Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54 15944534 - J Nucl Cardiol. 2005 May-Jun;12(3):294-301 25977567 - Arterioscler Thromb Vasc Biol. 2015 Jul;35(7):1696-703 17498586 - J Am Coll Cardiol. 2007 May 15;49(19):1991; author reply 1991-2 21353104 - Clin Ther. 2010 Dec;32(14):2337-47 11567186 - Nucl Med Commun. 2001 Oct;22(10):1123-8 22461139 - Ann Neurol. 2012 May;71(5):709-18 16282536 - Stroke. 2005 Dec;36(12):2642-7 21329844 - J Am Coll Cardiol. 2011 Feb 22;57(8):971-6 15235073 - J Nucl Med. 2004 Jul;45(7):1245-50 22038986 - Circ Cardiovasc Imaging. 2012 Jan;5(1):69-77 20223427 - JACC Cardiovasc Imaging. 2010 Mar;3(3):289-95 17084256 - J Am Coll Cardiol. 2006 Nov 7;48(9):1818-24 17719477 - J Am Coll Cardiol. 2007 Aug 28;50(9):892-6 23404088 - J Nucl Med. 2013 Mar;54(3):402-15 18927453 - Stroke. 2009 Jan;40(1):86-93 25488268 - Nat Rev Cardiol. 2015 Feb;12(2):79 23727083 - J Am Coll Cardiol. 2013 Sep 3;62(10):909-17 25827619 - J Nucl Cardiol. 2015 Jun;22(3):468-79 19443587 - J Nucl Med. 2009 Jun;50(6):854-7 23973698 - J Am Coll Cardiol. 2014 Jan 7-14;63(1):86-8 25722452 - J Nucl Med. 2015 Apr;56(4):552-9 21908036 - Lancet. 2011 Oct 29;378(9802):1547-59 12029209 - Nucl Med Commun. 2002 Jun;23(6):545-50 20554733 - J Nucl Med. 2010 Jul;51(7):1015-20 22651864 - J Am Coll Cardiol. 2012 Jun 5;59(23):2080-8 19690022 - J Nucl Med. 2009 Sep;50(9):1560; author reply 1560-1 17039492 - J Surg Oncol. 2006 Dec 1;94(7):607-13 20484438 - J Nucl Med. 2010 Jun;51(6):862-5 24269261 - JACC Cardiovasc Imaging. 2013 Dec;6(12):1250-9 10413738 - N Engl J Med. 1999 Jul 22;341(4):248-57 11440033 - Eur J Nucl Med. 2001 Jun;28(6):730-5 24271038 - Eur J Nucl Med Mol Imaging. 2014 Feb;41(2):369-83 24556608 - Phys Med Biol. 2014 Mar 7;59(5):1203-22 20080898 - J Nucl Med. 2010 Feb;51(2):193-7 24099932 - Phys Med Biol. 2013 Nov 7;58(21):7527-42 17504879 - J Nucl Med. 2007 Jun;48(6):932-45 22109668 - Eur J Nucl Med Mol Imaging. 2012 Mar;39(3):399-407 23359660 - J Nucl Med. 2013 Apr;54(4):647-58 25212803 - JACC Cardiovasc Imaging. 2014 Sep;7(9):959-60 21835280 - Am Heart J. 2011 Aug;162(2):214-221.e2 17084257 - J Am Coll Cardiol. 2006 Nov 7;48(9):1825-31 11239408 - Cell. 2001 Feb 23;104(4):503-16 24442596 - Eur J Nucl Med Mol Imaging. 2014 May;41(5):934-45 21321276 - J Nucl Med. 2011 Mar;52(3):362-8 18183393 - Eur J Nucl Med Mol Imaging. 2008 Apr;35(4):815-20 25752438 - Atherosclerosis. 2015 May;240(1):53-60 17125772 - Atherosclerosis. 2007 Jun;192(2):453-4; author reply 451-2 25997038 - Medicine (Baltimore). 2015 May;94(20):e725 18376410 - Nat Med. 2008 Apr;14(4):459-65 17229946 - N Engl J Med. 2007 Jan 18;356(3):209-11 23073343 - Phys Med Biol. 2012 Nov 7;57(21):R119-59 24224999 - Lancet. 2014 Feb 22;383(9918):705-13 24488982 - Circ Cardiovasc Imaging. 2014 May;7(3):454-60 12057982 - Circulation. 2002 Jun 11;105(23):2708-11 24475026 - PLoS One. 2014;9(1):e83094 21518602 - Chin Med J (Engl). 2011 Mar;124(6):911-7 19430785 - Eur J Nucl Med Mol Imaging. 2009 Oct;36(10):1622-8 12066187 - Nature. 2002 Jun 13;417(6890):750-4 24070911 - J Am Coll Cardiol. 2013 Dec 24;62(25):2382-91 |
| References_xml | – reference: ZhaoSKugeYTsukamotoEMochizukiTKatoTHikosakaKFluorodeoxyglucose uptake and glucose transporter expression in experimental inflammatory lesions and malignant tumours: effects of insulin and glucose loadingNucl Med Commun20022354555010.1097/00006231-200206000-00006120292091:CAS:528:DC%2BD38XntFSmur4%3D – reference: DerlinTRichterUBannasPBegemannPBuchertRMesterJFeasibility of 18F-sodium fluoride PET/CT for imaging of atherosclerotic plaqueJ Nucl Med20105186286510.2967/jnumed.110.07647120484438 – reference: RomingerASaamTWolpersSCyranCCSchmidtMFoersterS18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic diseaseJ Nucl Med2009501611162010.2967/jnumed.109.06515119759117 – reference: PetibonYEl FakhriGNezafatRJohnsonNBradyTOuyangJTowards coronary plaque imaging using simultaneous PET-MR: a simulation studyPhys Med Biol20145912031222406160710.1088/0031-9155/59/5/1203245566081:STN:280:DC%2BC2cvmvFChtA%3D%3D – reference: Izquierdo-GarciaDDaviesJRGravesMJRuddJHGillardJHWeissbergPLComparison of methods for magnetic resonance-guided [18-F]fluorodeoxyglucose positron emission tomography in human carotid arteries: reproducibility, partial volume correction, and correlation between methodsStroke200940869310.1161/STROKEAHA.108.52139318927453 – reference: ShaddingerBCXuYRogerJHMacpheeCHHandelMBaidooCAPlatelet aggregation unchanged by lipoprotein-associated phospholipase A2 inhibition: results from an in vitro study and two randomized phase I trialsPLoS One201427e8309 – reference: RuddJHMyersKSBansilalSMachacJRafiqueAFarkouhM(18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trialsJ Am Coll Cardiol20075089289610.1016/j.jacc.2007.05.02417719477 – reference: HuetPBurgSLe GuludecDHyafilFBuvatIVariability and uncertainty of 18F-FDG PET imaging protocols for assessing inflammation in atherosclerosis: suggestions for improvementJ Nucl Med20155655255910.2967/jnumed.114.142596257224521:CAS:528:DC%2BC2MXmvVWmtLc%3D – reference: RabkinZIsraelOKeidarZDo hyperglycemia and diabetes affect the incidence of false-negative 18F-FDG PET/CT studies in patients evaluated for infection or inflammation and cancer? A comparative analysisJ Nucl Med2010511015102010.2967/jnumed.109.07429420554733 – reference: TawakolAFayadZAMoggRAlonAKlimasMTDanskyHIntensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility studyJ Am Coll Cardiol20136290991710.1016/j.jacc.2013.04.066237270831:CAS:528:DC%2BC3sXhtlClu7zP – reference: Folke PedersenSVikjær SandholtBHøgild KellerSEspe HansenAEttrup ClemmensenASillesenH64Cu-DOTATATE PET/MRI for detection of activated macrophages in carotid atherosclerotic plaques: studies in patients undergoing endarterectomyArterioscler Thromb Vasc Biol2015351696170310.1161/ATVBAHA.114.3050671:CAS:528:DC%2BC2MXhtVKntbbL – reference: LeeWWChungJHJangSJEoJSParkSYSungSWConsideration of serum glucose levels during malignant mediastinal lymph node detection in non-small-cell lung cancer by FDG-PETJ Surg Oncol20069460761310.1002/jso.20624170394921:CAS:528:DC%2BD28XhtlCisb3I – reference: VirmaniRKolodgieFDBurkeAPFinnAVGoldHKTulenkoTNAtherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhageArterioscler Thromb Vasc Biol2005252054206110.1161/01.ATV.0000178991.71605.18160375671:CAS:528:DC%2BD2MXhtVCltrvL – reference: DaviesJRRuddJHFryerTDGravesMJClarkJCKirkpatrickPJIdentification of culprit lesions after transient ischemic attack by combined 18F fluorodeoxyglucose positron-emission tomography and high-resolution magnetic resonance imagingStroke2005362642264710.1161/01.STR.0000190896.67743.b116282536 – reference: KatoKSchoberOIkedaMSchäfersMIshigakiTKiesPEvaluation and comparison of 11C-choline uptake and calcification in aortic and common carotid arterial walls with combined PET/CTEur J Nucl Med Mol Imaging2009361622162810.1007/s00259-009-1152-7194307851:CAS:528:DC%2BD1MXht1WhtLzK – reference: MarnaneMMerwickASheehanOCHannonNForanPGrantTCarotid plaque inflammation on 18F-fluorodeoxyglucose positron emission tomography predicts early stroke recurrenceAnn Neurol20127170971810.1002/ana.2355322461139 – reference: BuceriusJManiVMoncrieffCMachacJFusterVFarkouhMEOptimizing 18F-FDG PET/CT imaging of vessel wall inflammation: the impact of 18F-FDG circulation time, injected dose, uptake parameters, and fasting blood glucose levelsEur J Nucl Med Mol Imaging201441369383402416610.1007/s00259-013-2569-6242710381:CAS:528:DC%2BC3sXhvVyhs77F – reference: TarkinJMRuddJHTechniques for noninvasive molecular imaging of atherosclerotic plaqueNat Rev Cardiol2014127910.1038/nrcardio.2014.80-c225488268 – reference: GaztanagaJFarkouhMRuddJHBrotzTMRosenbaumDManiVA phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndromeAtherosclerosis2015240536010.1016/j.atherosclerosis.2015.02.027257524381:CAS:528:DC%2BC2MXjsVGntLg%3D – reference: BuceriusJManiVWongSMoncrieffCIzquierdo-GarciaDMachacJArterial and fat tissue inflammation are highly correlated: a prospective 18F-FDG PET/CT studyEur J Nucl Med Mol Imaging201441934945402416710.1007/s00259-013-2653-y24442596 – reference: RuddJHMyersKSBansilalSMachacJPintoCATongCAtherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendationsJ Nucl Med20084987187810.2967/jnumed.107.05029418483100 – reference: BuceriusJVijgenGHBransBBouvyNDBauwensMRuddJHImpact of bariatric surgery on carotid artery inflammation and the metabolic activity in different adipose tissuesMedicine (Baltimore)201594e72510.1097/MD.00000000000007251:CAS:528:DC%2BC2MXptFKrtLg%3D – reference: EmamiHVucicESubramanianSAbdelbakyAFayadZADuSThe effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: a multicenter FDG-PET trialAtherosclerosis201524049049610.1016/j.atherosclerosis.2015.03.039259136641:CAS:528:DC%2BC2MXls1Gmsr8%3D – reference: RischplerCNekollaSGDregelyISchwaigerMHybrid PET/MR imaging of the heart: potential, initial experiences, and future prospectsJ Nucl Med20135440241510.2967/jnumed.112.105353234040881:CAS:528:DC%2BC3sXltV2ksrk%3D – reference: WuYWKaoHLHuangCLChenMFLinLYWangYCThe effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkersEur J Nucl Med Mol Imaging20113939940710.1007/s00259-011-1994-7221096681:CAS:528:DC%2BC38XitlGjurY%3D – reference: ChenWDilsizianVPET assessment of vascular inflammation and atherosclerotic plaques: SUV or TBR?J Nucl Med20155650350410.2967/jnumed.115.154385257224511:CAS:528:DC%2BC2MXmvVWmtb0%3D – reference: FayadZAManiVWoodwardMKallendDBansilalSPozzaJRationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomographyAm Heart J2011162214221404782010.1016/j.ahj.2011.05.006218352801:CAS:528:DC%2BC3MXhtVajtrvF – reference: FigueroaALAbdelbakyATruongQACorsiniEMacNabbMHLavenderZRMeasurement of arterial activity on routine FDG PET/CT images improves prediction of risk of future CV eventsJACC Cardiovasc Imaging201361250125910.1016/j.jcmg.2013.08.00624269261 – reference: RomingerASaamTVoglEÜbleisCla FougèreCFörsterSIn vivo imaging of macrophage activity in the coronary arteries using 68Ga-DOTATATE PET/CT: correlation with coronary calcium burden and risk factorsJ Nucl Med20105119319710.2967/jnumed.109.07067220080898 – reference: IrkleAVeseyATLewisDYSkepperJNBirdJLDweckMRIdentifying active vascular microcalcification by (18)F-sodium fluoride positron emission tomographyNat Commun201567495450699710.1038/ncomms849526151378 – reference: JamarFBuscombeJChitiAChristianPEDelbekeDDonohoeKJEANM/SNMMI guideline for 18F-FDG use in inflammation and infectionJ Nucl Med20135464765810.2967/jnumed.112.11252423359660 – reference: BuceriusJManiVMoncrieffCRuddJHMachacJFusterVImpact of non insulin-dependent type 2 diabetes on carotid wall (18)F-fluorodeoxyglucose positron emission tomography uptakeJ Am Coll Cardiol20125920802088339220210.1016/j.jacc.2011.11.06922651864 – reference: ZhaoSKugeYTsukamotoEMochizukiTKatoTHikosakaKEffects of insulin and glucose loading on FDG uptake in experimental malignant tumours and inflammatory lesionsEur J Nucl Med20012873073510.1007/s002590100517114400331:CAS:528:DC%2BD3MXktlaksr4%3D – reference: BoellaardRDelgado-BoltonROyenWJGiammarileFTatschKEschnerWFDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0Eur J Nucl Med Mol Imaging201542328354431552910.1007/s00259-014-2961-x254522191:CAS:528:DC%2BC2cXitVWhu7rL – reference: PedersenSFGraebeMFisker HagAMHøjgaardLSillesenHKjaerAGene expression and 18FDG uptake in atherosclerotic carotid plaquesNucl Med Commun201031423429201455771:CAS:528:DC%2BC3cXmtVWjsLw%3D – reference: DerlinTWisotzkiCRichterUApostolovaIBannasPWeberCIn vivo imaging of mineral deposition in carotid plaque using 18F-sodium fluoride PET/CT: correlation with atherogenic risk factorsJ Nucl Med20115236236810.2967/jnumed.110.08120821321276 – reference: BurgSDupasAStuteSDieudonnéAHuetPLe GuludecDPartial volume effect estimation and correction in the aortic vascular wall in PET imagingPhys Med Biol2013587527754210.1088/0031-9155/58/21/7527240999321:STN:280:DC%2BC2c%2FjtlWksg%3D%3D – reference: ErlandssonKBuvatIPretoriusPHThomasBAHuttonBFA review of partial volume correction techniques for emission tomography and their applications in neurology, cardiology and oncologyPhys Med Biol201257R119R15910.1088/0031-9155/57/21/R11923073343 – reference: Rudd JH, Machac J, Fayad ZA. Simvastatin and plaque inflammation. J Am Coll Cardiol. 2007;49:1991. Author reply 1991–2. – reference: Rudd JH, Fayad ZA, Machac J, Weissberg PL, Davies JR, Warburton EA, et al. Response to 'Laurberg JM, Olsen AK, Hansen SB, Bottcher M, Morrison M, Ricketts SA, Falk E. Imaging of vulnerable atherosclerotic plaques with FDG-microPET: no FDG accumulation' [Atherosclerosis 2006]. Atherosclerosis. 2007;192:453–4. Author reply 451–2. – reference: FiferKMQadirSSubramanianSVijayakumarJFigueroaALTruongQAPositron emission tomography measurement of periodontal 18F-fluorodeoxyglucose uptake is associated with histologically determined carotid plaque inflammationJ Am Coll Cardiol20115797197610.1016/j.jacc.2010.09.05621329844 – reference: KimEJKimSKangDOSeoHSMetabolic activity of the spleen and bone marrow in patients with acute myocardial infarction evaluated by 18F-fluorodeoxyglucose positron emission tomographic imagingCirc Cardiovasc Imaging2014745446010.1161/CIRCIMAGING.113.00109324488982 – reference: MozaffarianDBenjaminEJGoASArnettDKBlahaMJCushmanMAmerican Heart Association Statistics Committee and Stroke Statistics SubcommitteeHeart disease and stroke statistics – 2015 update: a report from the American Heart AssociationCirculation2015131e29e32210.1161/CIR.000000000000015225520374The current online version of the article, with corrections, is available at http://circ.ahajournals.org/content/131/4/e29.full – reference: BuceriusJSchmaljohannJBöhmIGuhlkeSPalmedoHSchildHHFeasibility of 18-F-Fluoromethylcholine PET/CT for imaging of vessel wall alterations in humans – first resultsEur J Nucl Med Mol Imaging20083581582010.1007/s00259-007-0685-x18183393 – reference: WHO. Cardiovascular diseases (CVDs). Fact sheet no. 317. Geneva: World Health Organization; 2015. http://www.who.int/mediacentre/factsheets/fs317/en/. – reference: RuddJHWarburtonEAFryerTDJonesHAClarkJCAntounNImaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomographyCirculation20021052708271110.1161/01.CIR.0000020548.60110.76120579821:STN:280:DC%2BD38zhsFCisg%3D%3D – reference: EmamiHVijayakumarJSubramanianSVucicESinghPMacNabbMHArterial 18F-FDG uptake in rheumatoid arthritis correlates with synovial activityJACC Cardiovasc Imaging2014795996010.1016/j.jcmg.2014.03.01825212803 – reference: SoretMBacharachSLBuvatIPartial-volume effect in PET tumor imagingJ Nucl Med20074893294510.2967/jnumed.106.03577417504879 – reference: FörsterSRomingerASaamTWolpersSNikolaouKCummingP18F-fluoroethylcholine uptake in arterial vessel walls and cardiovascular risk factors. Correlation in a PET-CT studyNuklearmedizin20104914815310.3413/nukmed-029920532464 – reference: OgawaMIshinoSMukaiTAsanoDTeramotoNWatabeH(18)F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging studyJ Nucl Med20044512451250152350731:CAS:528:DC%2BD2cXnsFygsbg%3D – reference: BaiBBadingJContiPSTumor quantification in clinical positron emission tomographyTheranostics20133787801384041210.7150/thno.562924312151 – reference: JudenhoferMSWehrlHFNewportDFCatanaCSiegelSBBeckerMSimultaneous PET-MRI: a new approach for functional and morphological imagingNat Med20081445946510.1038/nm1700183764101:CAS:528:DC%2BD1cXktl2is7k%3D – reference: GraebeMPedersenSFHøjgaardLKjaerASillesenH18FDG PET and ultrasound echolucency in carotid artery plaquesJACC Cardiovasc Imaging2010328929510.1016/j.jcmg.2010.01.00120223427 – reference: MillerYIChangMKBinderCJShawPXWitztumJLOxidized low density lipoprotein and innate immune receptorsCurr Opin Lipidol20031443744510.1097/00041433-200310000-00004145015821:CAS:528:DC%2BD3sXntlyrt7Y%3D – reference: TawakolAMigrinoRQBashianGGBedriSVermylenDCuryRCIn vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patientsJ Am Coll Cardiol2006481818182410.1016/j.jacc.2006.05.07617084256 – reference: GholamiSSalavatiAHoushmandSWernerTJAlaviAAssessment of atherosclerosis in large vessel walls: A comprehensive review of FDG-PET/CT image acquisition protocols and methods for uptake quantificationJ Nucl Cardiol20152246847910.1007/s12350-015-0069-825827619 – reference: BlombergBAThomassenATakxRAHildebrandtMGSimonsenJABuch-OlsenKMDelayed 18F-fluorodeoxyglucose PET/CT imaging improves quantitation of atherosclerotic plaque inflammation: results from the CAMONA studyJ Nucl Cardiol20142158859710.1007/s12350-014-9884-624633502 – reference: SkålénKGustafssonMRydbergEKHulténLMWiklundOInnerarityTLSubendothelial retention of atherogenic lipoproteins in early atherosclerosisNature200241775075410.1038/nature00804120661871:CAS:528:DC%2BD38XksVGjuro%3D – reference: SubramanianSEmamiHVucicESinghPVijayakumarJFiferKMHigh-dose atorvastatin reduces periodontal inflammation: a novel pleiotropic effect of statinsJ Am Coll Cardiol2013622382239110.1016/j.jacc.2013.08.1627240709111:CAS:528:DC%2BC3sXitVWmsrbJ – reference: FigueroaALSubramanianSSCuryRCTruongQAGardeckiJATearneyGJDistribution of inflammation within carotid atherosclerotic plaques with high-risk morphological features: a comparison between positron emission tomography activity, plaque morphology, and histopathologyCirc Cardiovasc Imaging20125697710.1161/CIRCIMAGING.110.95947822038986 – reference: RuddJHElkhawadMFayadZAVascular imaging with 18F-FDG PET/CT: optimal 18F-FDG circulation time?J Nucl Med200950156010.2967/jnumed.109.06645619690022 – reference: AbdelbakyACorsiniEFigueroaALFontanezSSubramanianSFerencikMFocal arterial inflammation precedes subsequent calcification in the same location: a longitudinal FDG-PET/CT studyCirc Cardiovasc Imaging2013674775410.1161/CIRCIMAGING.113.00038223833282 – reference: RuddJHHyafilFFayadZAInflammation imaging in atherosclerosisArterioscler Thromb Vasc Biol20092910091016283658610.1161/ATVBAHA.108.165563193046731:CAS:528:DC%2BD1MXntVymtL4%3D – reference: IshiiHNishioMTakahashiHAoyamaTTanakaMToriyamaTComparison of atorvastatin 5 and 20 mg/d for reducing F-18 fluorodeoxyglucose uptake in atherosclerotic plaques on positron emission tomography/computed tomography: a randomized, investigator-blinded, open-label, 6-month study in Japanese adults scheduled for percutaneous coronary interventionClin Ther2010322337234710.1016/j.clinthera.2010.12.001213531041:CAS:528:DC%2BC3MXisFKjsrw%3D – reference: ZhuangHMCortés-BlancoAPourdehnadMAdamLEYamamotoAJMartínez-LázaroRDo high glucose levels have differential effect on FDG uptake in inflammatory and malignant disorders?Nucl Med Commun2001221123112810.1097/00006231-200110000-00011115671861:STN:280:DC%2BD3MritVWhug%3D%3D – reference: ElkhawadMRuddJHSarov-BlatLCaiGWellsRDaviesLCEffects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosisJACC Cardiovasc Imaging2012591192210.1016/j.jcmg.2012.02.01622974804 – reference: TaharaNKaiHIshibashiMNakauraHKaidaHBabaKSimvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomographyJ Am Coll Cardiol2006481825183110.1016/j.jacc.2006.03.069170842571:CAS:528:DC%2BD28XhtFOjtb%2FE – reference: AndersonGFChuEExpanding priorities – confronting chronic disease in countries with low incomeN Engl J Med200735620921110.1056/NEJMp068182172299461:CAS:528:DC%2BD2sXns1yktA%3D%3D – reference: ZhaoQMFengTTZhaoXXuZMLiuYLiDPImaging of atherosclerotic aorta of rabbit model by detection of plaque inflammation with fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomographyChin Med J (Engl)20111249119171:CAS:528:DC%2BC3MXltleqtLo%3D – reference: TawakolASinghPRuddJHSofferJCaiGVucicEEffect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with (18)F-fluorodeoxyglucose-positron emission tomography imagingJ Am Coll Cardiol201463868810.1016/j.jacc.2013.07.050239736981:CAS:528:DC%2BC2cXltVSmsw%3D%3D – reference: GlassCKWitztumJLAtherosclerosis. the road aheadCell200110450351610.1016/S0092-8674(01)00238-0112394081:CAS:528:DC%2BD3MXis1Kksrc%3D – reference: JoshiNVVeseyATWilliamsMCShahASCalvertPACraigheadFH18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trialLancet201438370571310.1016/S0140-6736(13)61754-724224999 – reference: ShepherdPRKahnBBGlucose transporters and insulin action – implications for insulin resistance and diabetes mellitusN Engl J Med199934124825710.1056/NEJM199907223410406104137381:CAS:528:DyaK1MXltVOju74%3D – reference: FayadZAManiVWoodwardMKallendDAbtMBurgessTSafety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trialLancet201137815471559415187510.1016/S0140-6736(11)61383-4219080361:CAS:528:DC%2BC3MXhtlyktr7P – reference: TawakolAMigrinoRQHoffmannUAbbaraSHouserSGewirtzHNoninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomographyJ Nucl Cardiol20051229430110.1016/j.nuclcard.2005.03.00215944534 – reference: MenezesLJKotzeCWHuttonBFEndozoRDicksonJCCullumIVascular inflammation imaging with 18F-FDG PET/CT: when to image?J Nucl Med20095085485710.2967/jnumed.108.06143219443587 – volume: 41 start-page: 369 year: 2014 ident: 3259_CR13 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-013-2569-6 – volume: 49 start-page: 148 year: 2010 ident: 3259_CR70 publication-title: Nuklearmedizin doi: 10.3413/nukmed-0299 – volume: 51 start-page: 193 year: 2010 ident: 3259_CR71 publication-title: J Nucl Med doi: 10.2967/jnumed.109.070672 – ident: 3259_CR16 doi: 10.1016/j.jacc.2007.03.003 – volume: 58 start-page: 7527 year: 2013 ident: 3259_CR33 publication-title: Phys Med Biol doi: 10.1088/0031-9155/58/21/7527 – volume: 56 start-page: 503 year: 2015 ident: 3259_CR51 publication-title: J Nucl Med doi: 10.2967/jnumed.115.154385 – volume: 124 start-page: 911 year: 2011 ident: 3259_CR39 publication-title: Chin Med J (Engl) – volume: 57 start-page: 971 year: 2011 ident: 3259_CR12 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2010.09.056 – volume: 23 start-page: 545 year: 2002 ident: 3259_CR28 publication-title: Nucl Med Commun doi: 10.1097/00006231-200206000-00006 – volume: 341 start-page: 248 year: 1999 ident: 3259_CR25 publication-title: N Engl J Med doi: 10.1056/NEJM199907223410406 – volume: 36 start-page: 1622 year: 2009 ident: 3259_CR69 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-009-1152-7 – volume: 240 start-page: 53 year: 2015 ident: 3259_CR63 publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2015.02.027 – volume: 417 start-page: 750 year: 2002 ident: 3259_CR4 publication-title: Nature doi: 10.1038/nature00804 – volume: 29 start-page: 1009 year: 2009 ident: 3259_CR8 publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/ATVBAHA.108.165563 – ident: 3259_CR1 – volume: 14 start-page: 459 year: 2008 ident: 3259_CR66 publication-title: Nat Med doi: 10.1038/nm1700 – volume: 378 start-page: 1547 year: 2011 ident: 3259_CR62 publication-title: Lancet doi: 10.1016/S0140-6736(11)61383-4 – volume: 22 start-page: 1123 year: 2001 ident: 3259_CR23 publication-title: Nucl Med Commun doi: 10.1097/00006231-200110000-00011 – volume: 39 start-page: 399 year: 2011 ident: 3259_CR60 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-011-1994-7 – volume: 6 start-page: 1250 year: 2013 ident: 3259_CR41 publication-title: JACC Cardiovasc Imaging doi: 10.1016/j.jcmg.2013.08.006 – volume: 6 start-page: 747 year: 2013 ident: 3259_CR57 publication-title: Circ Cardiovasc Imaging doi: 10.1161/CIRCIMAGING.113.000382 – volume: 383 start-page: 705 year: 2014 ident: 3259_CR76 publication-title: Lancet doi: 10.1016/S0140-6736(13)61754-7 – volume: 356 start-page: 209 year: 2007 ident: 3259_CR2 publication-title: N Engl J Med doi: 10.1056/NEJMp068182 – volume: 131 start-page: e29 year: 2015 ident: 3259_CR3 publication-title: Circulation doi: 10.1161/CIR.0000000000000152 – volume: 3 start-page: 787 year: 2013 ident: 3259_CR43 publication-title: Theranostics doi: 10.7150/thno.5629 – volume: 52 start-page: 362 year: 2011 ident: 3259_CR75 publication-title: J Nucl Med doi: 10.2967/jnumed.110.081208 – volume: 240 start-page: 490 year: 2015 ident: 3259_CR52 publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2015.03.039 – volume: 48 start-page: 1825 year: 2006 ident: 3259_CR19 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2006.03.069 – volume: 56 start-page: 552 year: 2015 ident: 3259_CR34 publication-title: J Nucl Med doi: 10.2967/jnumed.114.142596 – volume: 49 start-page: 871 year: 2008 ident: 3259_CR42 publication-title: J Nucl Med doi: 10.2967/jnumed.107.050294 – volume: 71 start-page: 709 year: 2012 ident: 3259_CR56 publication-title: Ann Neurol doi: 10.1002/ana.23553 – volume: 6 start-page: 7495 year: 2015 ident: 3259_CR74 publication-title: Nat Commun doi: 10.1038/ncomms8495 – volume: 50 start-page: 892 year: 2007 ident: 3259_CR40 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2007.05.024 – volume: 25 start-page: 2054 year: 2005 ident: 3259_CR7 publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/01.ATV.0000178991.71605.18 – volume: 27 start-page: e8309 year: 2014 ident: 3259_CR65 publication-title: PLoS One – volume: 104 start-page: 503 year: 2001 ident: 3259_CR5 publication-title: Cell doi: 10.1016/S0092-8674(01)00238-0 – volume: 22 start-page: 468 year: 2015 ident: 3259_CR38 publication-title: J Nucl Cardiol doi: 10.1007/s12350-015-0069-8 – volume: 50 start-page: 1611 year: 2009 ident: 3259_CR55 publication-title: J Nucl Med doi: 10.2967/jnumed.109.065151 – volume: 36 start-page: 2642 year: 2005 ident: 3259_CR11 publication-title: Stroke doi: 10.1161/01.STR.0000190896.67743.b1 – volume: 7 start-page: 959 year: 2014 ident: 3259_CR49 publication-title: JACC Cardiovasc Imaging doi: 10.1016/j.jcmg.2014.03.018 – volume: 50 start-page: 854 year: 2009 ident: 3259_CR15 publication-title: J Nucl Med doi: 10.2967/jnumed.108.061432 – volume: 28 start-page: 730 year: 2001 ident: 3259_CR27 publication-title: Eur J Nucl Med doi: 10.1007/s002590100517 – volume: 7 start-page: 454 year: 2014 ident: 3259_CR46 publication-title: Circ Cardiovasc Imaging doi: 10.1161/CIRCIMAGING.113.001093 – volume: 162 start-page: 214 year: 2011 ident: 3259_CR61 publication-title: Am Heart J doi: 10.1016/j.ahj.2011.05.006 – volume: 94 start-page: 607 year: 2006 ident: 3259_CR24 publication-title: J Surg Oncol doi: 10.1002/jso.20624 – volume: 62 start-page: 2382 year: 2013 ident: 3259_CR48 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2013.08.1627 – volume: 21 start-page: 588 year: 2014 ident: 3259_CR20 publication-title: J Nucl Cardiol doi: 10.1007/s12350-014-9884-6 – volume: 63 start-page: 86 year: 2014 ident: 3259_CR64 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2013.07.050 – volume: 12 start-page: 79 year: 2014 ident: 3259_CR58 publication-title: Nat Rev Cardiol doi: 10.1038/nrcardio.2014.80-c2 – volume: 54 start-page: 647 year: 2013 ident: 3259_CR26 publication-title: J Nucl Med doi: 10.2967/jnumed.112.112524 – volume: 59 start-page: 1203 year: 2014 ident: 3259_CR35 publication-title: Phys Med Biol doi: 10.1088/0031-9155/59/5/1203 – volume: 48 start-page: 932 year: 2007 ident: 3259_CR32 publication-title: J Nucl Med doi: 10.2967/jnumed.106.035774 – volume: 5 start-page: 69 year: 2012 ident: 3259_CR10 publication-title: Circ Cardiovasc Imaging doi: 10.1161/CIRCIMAGING.110.959478 – volume: 48 start-page: 1818 year: 2006 ident: 3259_CR9 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2006.05.076 – volume: 32 start-page: 2337 year: 2010 ident: 3259_CR59 publication-title: Clin Ther doi: 10.1016/j.clinthera.2010.12.001 – volume: 35 start-page: 1696 year: 2015 ident: 3259_CR72 publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/ATVBAHA.114.305067 – volume: 31 start-page: 423 year: 2010 ident: 3259_CR54 publication-title: Nucl Med Commun doi: 10.1097/MNM.0b013e32833767e0 – volume: 35 start-page: 815 year: 2008 ident: 3259_CR68 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-007-0685-x – volume: 51 start-page: 1015 year: 2010 ident: 3259_CR22 publication-title: J Nucl Med doi: 10.2967/jnumed.109.074294 – volume: 54 start-page: 402 year: 2013 ident: 3259_CR67 publication-title: J Nucl Med doi: 10.2967/jnumed.112.105353 – volume: 40 start-page: 86 year: 2009 ident: 3259_CR36 publication-title: Stroke doi: 10.1161/STROKEAHA.108.521393 – volume: 59 start-page: 2080 year: 2012 ident: 3259_CR30 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2011.11.069 – volume: 105 start-page: 2708 year: 2002 ident: 3259_CR14 publication-title: Circulation doi: 10.1161/01.CIR.0000020548.60110.76 – volume: 50 start-page: 1560 year: 2009 ident: 3259_CR18 publication-title: J Nucl Med doi: 10.2967/jnumed.109.066456 – volume: 3 start-page: 289 year: 2010 ident: 3259_CR53 publication-title: JACC Cardiovasc Imaging doi: 10.1016/j.jcmg.2010.01.001 – volume: 41 start-page: 934 year: 2014 ident: 3259_CR44 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-013-2653-y – volume: 51 start-page: 862 year: 2010 ident: 3259_CR73 publication-title: J Nucl Med doi: 10.2967/jnumed.110.076471 – ident: 3259_CR17 doi: 10.1016/j.atherosclerosis.2006.10.027 – volume: 45 start-page: 1245 year: 2004 ident: 3259_CR37 publication-title: J Nucl Med – volume: 94 start-page: e725 year: 2015 ident: 3259_CR45 publication-title: Medicine (Baltimore) doi: 10.1097/MD.0000000000000725 – volume: 5 start-page: 911 year: 2012 ident: 3259_CR47 publication-title: JACC Cardiovasc Imaging doi: 10.1016/j.jcmg.2012.02.016 – volume: 14 start-page: 437 year: 2003 ident: 3259_CR6 publication-title: Curr Opin Lipidol doi: 10.1097/00041433-200310000-00004 – volume: 12 start-page: 294 year: 2005 ident: 3259_CR21 publication-title: J Nucl Cardiol doi: 10.1016/j.nuclcard.2005.03.002 – volume: 42 start-page: 328 year: 2015 ident: 3259_CR29 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-014-2961-x – volume: 62 start-page: 909 year: 2013 ident: 3259_CR50 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2013.04.066 – volume: 57 start-page: R119 year: 2012 ident: 3259_CR31 publication-title: Phys Med Biol doi: 10.1088/0031-9155/57/21/R119 – reference: 24556608 - Phys Med Biol. 2014 Mar 7;59(5):1203-22 – reference: 23359660 - J Nucl Med. 2013 Apr;54(4):647-58 – reference: 23727083 - J Am Coll Cardiol. 2013 Sep 3;62(10):909-17 – reference: 24271038 - Eur J Nucl Med Mol Imaging. 2014 Feb;41(2):369-83 – reference: 24488982 - Circ Cardiovasc Imaging. 2014 May;7(3):454-60 – reference: 21321276 - J Nucl Med. 2011 Mar;52(3):362-8 – reference: 24099932 - Phys Med Biol. 2013 Nov 7;58(21):7527-42 – reference: 25452219 - Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54 – reference: 24442596 - Eur J Nucl Med Mol Imaging. 2014 May;41(5):934-45 – reference: 16282536 - Stroke. 2005 Dec;36(12):2642-7 – reference: 17229946 - N Engl J Med. 2007 Jan 18;356(3):209-11 – reference: 12029209 - Nucl Med Commun. 2002 Jun;23(6):545-50 – reference: 20080898 - J Nucl Med. 2010 Feb;51(2):193-7 – reference: 14501582 - Curr Opin Lipidol. 2003 Oct;14(5):437-45 – reference: 22651864 - J Am Coll Cardiol. 2012 Jun 5;59(23):2080-8 – reference: 24475026 - PLoS One. 2014;9(1):e83094 – reference: 25212803 - JACC Cardiovasc Imaging. 2014 Sep;7(9):959-60 – reference: 23073343 - Phys Med Biol. 2012 Nov 7;57(21):R119-59 – reference: 17084257 - J Am Coll Cardiol. 2006 Nov 7;48(9):1825-31 – reference: 10413738 - N Engl J Med. 1999 Jul 22;341(4):248-57 – reference: 11567186 - Nucl Med Commun. 2001 Oct;22(10):1123-8 – reference: 24070911 - J Am Coll Cardiol. 2013 Dec 24;62(25):2382-91 – reference: 24633502 - J Nucl Cardiol. 2014 Jun;21(3):588-97 – reference: 19690022 - J Nucl Med. 2009 Sep;50(9):1560; author reply 1560-1 – reference: 17084256 - J Am Coll Cardiol. 2006 Nov 7;48(9):1818-24 – reference: 21908036 - Lancet. 2011 Oct 29;378(9802):1547-59 – reference: 20554733 - J Nucl Med. 2010 Jul;51(7):1015-20 – reference: 21835280 - Am Heart J. 2011 Aug;162(2):214-221.e2 – reference: 25520374 - Circulation. 2015 Jan 27;131(4):e29-322 – reference: 11239408 - Cell. 2001 Feb 23;104(4):503-16 – reference: 19759117 - J Nucl Med. 2009 Oct;50(10):1611-20 – reference: 24269261 - JACC Cardiovasc Imaging. 2013 Dec;6(12):1250-9 – reference: 18183393 - Eur J Nucl Med Mol Imaging. 2008 Apr;35(4):815-20 – reference: 18483100 - J Nucl Med. 2008 Jun;49(6):871-8 – reference: 19430785 - Eur J Nucl Med Mol Imaging. 2009 Oct;36(10):1622-8 – reference: 21353104 - Clin Ther. 2010 Dec;32(14):2337-47 – reference: 25722451 - J Nucl Med. 2015 Apr;56(4):503-4 – reference: 20532464 - Nuklearmedizin. 2010;49(4):148-53 – reference: 25997038 - Medicine (Baltimore). 2015 May;94(20):e725 – reference: 23833282 - Circ Cardiovasc Imaging. 2013 Sep;6(5):747-54 – reference: 11440033 - Eur J Nucl Med. 2001 Jun;28(6):730-5 – reference: 12066187 - Nature. 2002 Jun 13;417(6890):750-4 – reference: 17498586 - J Am Coll Cardiol. 2007 May 15;49(19):1991; author reply 1991-2 – reference: 18376410 - Nat Med. 2008 Apr;14(4):459-65 – reference: 17719477 - J Am Coll Cardiol. 2007 Aug 28;50(9):892-6 – reference: 19443587 - J Nucl Med. 2009 Jun;50(6):854-7 – reference: 17504879 - J Nucl Med. 2007 Jun;48(6):932-45 – reference: 25722452 - J Nucl Med. 2015 Apr;56(4):552-9 – reference: 26151378 - Nat Commun. 2015;6:7495 – reference: 16037567 - Arterioscler Thromb Vasc Biol. 2005 Oct;25(10):2054-61 – reference: 18927453 - Stroke. 2009 Jan;40(1):86-93 – reference: 25752438 - Atherosclerosis. 2015 May;240(1):53-60 – reference: 24224999 - Lancet. 2014 Feb 22;383(9918):705-13 – reference: 20223427 - JACC Cardiovasc Imaging. 2010 Mar;3(3):289-95 – reference: 19304673 - Arterioscler Thromb Vasc Biol. 2009 Jul;29(7):1009-16 – reference: 20484438 - J Nucl Med. 2010 Jun;51(6):862-5 – reference: 17125772 - Atherosclerosis. 2007 Jun;192(2):453-4; author reply 451-2 – reference: 25913664 - Atherosclerosis. 2015 Jun;240(2):490-6 – reference: 22461139 - Ann Neurol. 2012 May;71(5):709-18 – reference: 25827619 - J Nucl Cardiol. 2015 Jun;22(3):468-79 – reference: 15944534 - J Nucl Cardiol. 2005 May-Jun;12(3):294-301 – reference: 17039492 - J Surg Oncol. 2006 Dec 1;94(7):607-13 – reference: 23973698 - J Am Coll Cardiol. 2014 Jan 7-14;63(1):86-8 – reference: 22974804 - JACC Cardiovasc Imaging. 2012 Sep;5(9):911-22 – reference: 21518602 - Chin Med J (Engl). 2011 Mar;124(6):911-7 – reference: 25977567 - Arterioscler Thromb Vasc Biol. 2015 Jul;35(7):1696-703 – reference: 22038986 - Circ Cardiovasc Imaging. 2012 Jan;5(1):69-77 – reference: 20145577 - Nucl Med Commun. 2010 May;31(5):423-9 – reference: 23404088 - J Nucl Med. 2013 Mar;54(3):402-15 – reference: 24312151 - Theranostics. 2013;3(10):787-801 – reference: 22109668 - Eur J Nucl Med Mol Imaging. 2012 Mar;39(3):399-407 – reference: 15235073 - J Nucl Med. 2004 Jul;45(7):1245-50 – reference: 25488268 - Nat Rev Cardiol. 2015 Feb;12(2):79 – reference: 21329844 - J Am Coll Cardiol. 2011 Feb 22;57(8):971-6 – reference: 12057982 - Circulation. 2002 Jun 11;105(23):2708-11 |
| SSID | ssj0018289 |
| Score | 2.5635624 |
| Snippet | Cardiovascular diseases are the leading cause of death not only in Europe but also in the rest of the World. Preventive measures, however, often fail and... |
| SourceID | pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 780 |
| SubjectTerms | Associations Atherosclerosis Atherosclerosis - diagnostic imaging Cardiology Guidelines Humans Imaging Medical imaging Medicine Medicine & Public Health Nuclear Medicine Oncology Orthopedics Positron-Emission Tomography - adverse effects Positron-Emission Tomography - methods Positron-Emission Tomography - standards Radiology Radiopharmaceuticals Tomography |
| SummonAdditionalLinks | – databaseName: Springer Nature Link OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1La9wwEBZtAqGX0qZp4jYtKvSQBwJp9T6GZUMo7JJDArkZWZbpQuNdss5v6N_ujNc22aQJ5GIMM7Jlz0j-xiN9Q8hPVWqsU1QyFbllqnCc-aQFq8BXRBKusG39lOnMXFyrXzf6piOLxr0wj_L3SPYJAB0CXs0knsi3ZFsLabFKw9iMh4QBBg4YW0E8wCy4cZ_A_N8lNj9BT3Dl0-WRj3Kk7afn_AN532FGerY28kfyJtW7ZGfaZcU_kb-X3corugzLdEcXFQVYR8cbS00pbgWZN01Kvbz_EU8fmAhlM6Q4hgb9DejR5Gw2PaYgvZxc0fltW9gINVv0uFiBOhznqz1yfT65Gl-wrsACi8arhglfjJzTQQcnQ-m5L6UEaynPVap8iM7G6HjilRhFlRLMjUJWVfQg01JLJT-TrXpRpwNCkwgl14UJHgM-mbwNtiwitE0xAOzJCO_feR479nEsgvEnH3iTWzPlYKYczZTLjJwMTZZr6o2XlA97Q-bdKFzlwlqYRJFyMCM_BjGMH0yKhDot7lHHYOrUcf-SjjUGq3W5jOyvfWPoEQAcAFkW7mA3vGZQQP7uTUk9_93yeCtrlBnZjJz2_vWg68896JdXaX8l7wDhmfVSo0Oy1dzdp2-Aopriezt-_gHdbhPQ priority: 102 providerName: Springer Nature |
| Title | Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM) on PET imaging of atherosclerosis |
| URI | https://link.springer.com/article/10.1007/s00259-015-3259-3 https://www.ncbi.nlm.nih.gov/pubmed/26678270 https://www.proquest.com/docview/1770883240 https://www.proquest.com/docview/1768166809 https://www.proquest.com/docview/1776648608 https://pubmed.ncbi.nlm.nih.gov/PMC4764627 |
| Volume | 43 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swEBdbC2MvY-u-vHVFgz3sAzE5kvXxVJI0WRkkhNFC3owsyzSw2Vnj_g37t3fn2G6zsrw4wXfCdu4k_053-R0hH2SeYJ-inEnPNZOZ4cyGJGYF-EocYpPppn_KbK7OL-X3ZbJsN9w2bVlltyY2C3Veedwj_xprDRMC6eNO178Zdo3C7GrbQuMhOUTqMvRqvewDrhijCQy4IEhgGny7y2ryhkQUgD8E0gkT-EXsvpfugc37NZP_JE6b99H0KXnSAkk63Fr-GXkQyiPyaNamyp-TP4u2HIuu3Tpc06qggPXoeKf-lOL_Q1Z1HUIn73bn6R27oWyOvMcwoLsA_TgZzmefKEgXkwu6-tV0O0LNBlJWG1CH42rzglxOJxfjc9Z2XWBeWVmz2GYDYxKXOCNcbrnNhQATSstlKKzzRntveOBFPPAyBFgwY1EU3oIsEYmQ4iU5KKsyvCY0xC7nSaacxShQBKudzjMPY4N3gIUiwrvfPPUtJTl2xviZ9mTKjZlSMFOKZkpFRD73Q9ZbPo59ysedIdN2am7SW0eKyPteDJMKMyWuDNUN6ijMpxpu9-lopbCFl4nIq61v9HcEqAeQl4Yr6B2v6RWQ1HtXUq6uGnJvqZVUAx2RL51_3bn1_z3om_0P-pY8BpyntgVHx-Sgvr4J7wBL1dlJM2HgaKbfTsjhcHQ2msLnaDJf_ICzYzX-C0ltIDw |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELfGkGAviP8EBhgJJP7IwomdOH5AaBotHVurPXTS3jLHcbRKkJQ1E-IT8G34jNylcViZ6Nteqkh3bpzcnf273PmOkJeyiLFPUcGk5YrJPOVMuzhkJehK6MI0V23_lPEkGR3JL8fx8Qb57c_CYFqlXxPbhbqoLX4jfx8qBQaB5eM-zr8z7BqF0VXfQmOpFvvu5w9w2RYf9j6BfF9F0XAw3R2xrqsAs4mWDQt1HqVpbGKTClNorgshYIpSc-lKbWyqrE2542UYWekcLAihKEurgRaLWEgB_3uNXJcCdnI8mT783Ect0HtBBw-cEqbAlnwUlbdFS8HRAMc9ZgIvxOo-eAncXs7R_CdQ2-5_w9vkVgdc6c5S0-6QDVfdJTfGXWj-Hvl12KV_0bmZuzNalxSwJd1dyXeleB5l1jTOebqPBtALeoK0CdZZhgH-BvT1YGcyfkOBejiY0tm3trsScrYQtl4AO_zOFvfJ0ZXI4wHZrOrKPSLUhabgcZ4YjV6ncFoZVeQWxjprAHsFhPt3ntmuBDp24via9cWbWzFlIKYMxZSJgLzth8yX9T_WMW97QWbdUrDI_ipuQF70ZDBijMyYytXnyJNg_Dbleh2PShJsGZYG5OFSN_oZAcoCpKfgDmpFa3oGLCK-Sqlmp20xcakSmUQqIO-8fl2Y-v8e9PH6B31Obo6m44PsYG-y_4RsAcZMlslO22SzOTt3TwHHNfmz1ngoOblqa_0DEzZX4w |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb5RAEJ_Ua9L4YvwvWnVNNPFPSIFdWPbBmNrepbUeuZg26RvCssRLFM4ejfET-J38dM4Aiz0b760vhGRmYZeZWX7DDDMAz0URUp-iwhXak67IY89VJvTdEnXFN36cy7Z_yjSJDk7Eh9PwdAN-239hKK3S7ontRl3Umr6R7_hSokFQ-bidsk-LmO1P3i2-u9RBiiKttp1GpyJH5ucPdN-Wbw_3UdYvgmAyPt47cPsOA66OlGhcX-VBHIdZmMU8K5SnCs5xukJ5wpQq07HUOvaMV_qBFsbg5uDzstQKaSEPueB43WuwKckrGsHm-3Ey-zTEMMiXIXcPXRRXomXZmKrXljBFtwPd-NDldMJX34qXoO7ljM1_wrbt23ByE270MJbtdnp3CzZMdRu2pn2g_g78mvXJYGyRLcwZq0uGSJPtrWS_Mvo7Zd40xli6jQ2wC1pDtISqLuMAewP2crybTF8xpM7Gx2z-re21RJwtoK2XyI7H-fIunFyJRO7BqKor8wCY8bPCC_MoU-SDcqNkJotc41ijM0RiDnj2mae6L4hOfTm-pkMp51ZMKYopJTGl3IHXw5BFVw1kHfO2FWTabwzL9K8aO_BsIKNJU5wmq0x9TjwRRXNjT63jkVFEDcRiB-53ujHMCDEX4j6Jd5ArWjMwUEnxVUo1_9KWFhcyElEgHXhj9evC1P-30IfrF_oUttBS04-HydEjuI6AM-oyn7Zh1Jydm8cI6pr8SW89DD5ftcH-AfpTXXU |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Position+paper+of+the+Cardiovascular+Committee+of+the+European+Association+of+Nuclear+Medicine+%28EANM%29+on+PET+imaging+of+atherosclerosis&rft.jtitle=European+journal+of+nuclear+medicine+and+molecular+imaging&rft.au=Bucerius%2C+Jan&rft.au=Hyafil%2C+Fabien&rft.au=Verberne%2C+Hein+J.&rft.au=Slart%2C+Riemer+H.+J.+A.&rft.date=2016-04-01&rft.pub=Springer+Berlin+Heidelberg&rft.issn=1619-7070&rft.eissn=1619-7089&rft.volume=43&rft.spage=780&rft.epage=792&rft_id=info:doi/10.1007%2Fs00259-015-3259-3&rft_id=info%3Apmid%2F26678270&rft.externalDocID=PMC4764627 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1619-7070&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1619-7070&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1619-7070&client=summon |